CLINICAL_TRIALS
trial_result
· 2025-11-28
Clinical Trial Update: Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis [Phase 2]
Summary
A dose-ranging Phase 2b study of ABX464 in moderate to severe ulcerative colitis has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Abivax S.A. | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2025-11-28